what is mounjaro tirzepatide FDA approves new version of diabetes drug to be sold for weight loss Switch to Tirzepatide in T2D

For Research Use Only Not for human or veterinary consumption Not evaluated by the FDA Supplied by Nextday Peptides for laboratory research applications only Research Use Only policy

Why This Matters for Your Treatment

Dec 22, 2025, 18:03 ET Average weight loss of ~17% if all patients stayed on treatment * with Wegovy (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment ** ) in the OASIS 4 trial 1 1.5 mg starting dose available in early January for $149 per month with savings offers

Consent to participate Written informed consent to participate in this case report was obtained from the patient

Mechanisms that protect against clots Direct platelet inhibition